TB Dispensary Arkhangelsk, Northern Russia
In Russia, MSF is collaborating with health authorities and academic partners in Arkhangelsk region to reduce the burden of drug-resistant tuberculosis and improve treatment for the disease.

In 2019, our teams in Arkhangelsk region began providing drugs and technical advice to support the treatment of patients with the most severe forms of TB in line with the latest World Health Organization recommendations. We are currently supporting the treatment of dozens of patients.

In partnership with Arkhangelsk Regional Ministry of Health, Northern State Medical University and Arkhangelsk Clinical TB Dispensary, we are building on existing expertise and working together to implement new all-oral short-course regimens. The aim of the collaboration is to provide evidence for future developments in TB policy in Russia and increase the availability of more effective models of treatment.  

MSF teams are also responding to the COVID-19 pandemic.

Our teams have been working in Russia since the early 1990s, running programmes in Moscow, Saint Petersburg, Kemerovo region, Chechnya, Ingushetia and Dagestan. 

Our activities in 2020 in Russia

Data and information from the International Activity Report 2020.

MSF in Russia in 2020 In Russia, MSF provides drugs and technical advice to support the treatment of patients with the most severe forms of TB. In 2020, we launched several new activities.
Russia Activities 2020

During the COVID-19 pandemic, MSF supported drug-resistant TB (DR-TB) patients with food parcels and health education about infection prevention measures. We also donated laboratory materials to Ministry of Health partners conducting COVID-19 testing.

In addition to our ongoing partnership with Arkhangelsk Regional Ministry of Health, Northern State Medical University and Arkhangelsk Clinical TB Dispensary, we entered into a technical agreement with the Regional TB Control Centre in Vladimir, to build on existing expertise and work together to implement novel, all-oral, short-course treatment regimens.

A study on oral short-course DR-TB regimens was approved by the Ethical Review Board of MSF and Ethical Research Committee of Northern State Medical University, with patient enrolment expected to begin in early 2021. The purpose of conducting the study in Arkhangelsk and Vladimir regions is to provide evidence for future developments in TB policy in Russia, and increase the availability of effective models of treatment that are more tolerable for patients.

In Moscow and Saint Petersburg, we work with two civil society organisations who offer high-quality healthcare to vulnerable people, including those living with HIV. People who are excluded from access to health clinics receive medical care through fixed and mobile units operated by these partners and supported by MSF.

In addition, during the COVID-19 pandemic, we delivered training and health education on prevention measures, and gave material support for hygiene and personal protective equipment for people treated by the civil society organisations. The training was adapted so it could be delivered online.

 

 
Russia

MSF strongly condemns kidnapping of head of Druzhba

Press Release 6 Aug 2002
 
Russia

Chechen displaced: MSF open letter to OCHA

Project Update 30 Jul 2002
 
Russia

Chechen displaced remain under pressure

Project Update 26 Jul 2002
 
Russia

MSF condemns relocation of displaced Chechens

Press Release 9 Jul 2002
 
Russia

MSF active in the three worst hit regions as well as in IDP camps in Ingushetia and Chechnya.

Project Update 27 Jun 2002
 
Russia

Letter to Danish Foreign Minister on the repatriation of Chechen IDPs in Ingushetia

Project Update 10 Jun 2002

Contact us

TB treatments yield promising results in the Chechen Republic
MSF Moscow

16 Malaya Dmitrovka street,
127006 Moscow,
Russian Federation